IRF3 activates RB to authorize cGAS-STING–induced senescence and mitigate liver fibrosis

分享:

简介:

  • 作者: QIROU WU, XIAOHONG LENG, QIAN ZHANG, YE-ZHANG ZHU, RUYUAN ZHOU, YUTONG LIU, CHEN MEI , DAN ZHANG, SHENGDUO LIU, SHASHA CHEN, XIAOJIAN WANG, AIFU LIN, XIA LIN, TINGBO LIANG, LI SHEN, XIN-HUA FENG, BING XIA, AND PINGLONG XU
  • 杂志: SCIENCE ADVANCES
  • Doi: https://www.doi.org/10.1126/sciadv.adj2102
  • 出版日期: 2024 Feb 28

论文中使用的产品/服务

Quotation shows PackGene:HSC- specific deletion of IRF3 was obtained by injection of AAV8 bearing GFAP (promoter)–EGFP- Cre into Irf3flox/flox mice through tail vein injection at a dose of 1 × 1011 virus genome (PackGene Biotech), twice in 2 weeks.

Research Field:liver fibrosis

AAV Serotype:AAV8

Targeted organ:liver

Animal or cell line strain:mice

询价

摘要

Cytosolic double-stranded DNA surveillance by cyclic GMP-AMP synthase (cGAS)–Stimulator of Interferon Genes (STING) signaling triggers cellular senescence, autophagy, biased mRNA translation, and interferon-mediated immune responses. However, detailed mechanisms and physiological relevance of STING-induced senescence are not fully understood. Here, we unexpectedly found that interferon regulatory factor 3 (IRF3), activated during innate DNA sensing, forms substantial endogenous complexes in the nucleus with retinoblastoma (RB), a key cell cycle regulator. The IRF3-RB interaction attenuates cyclin-dependent kinase 4/6 (CDK4/6)–mediated RB hyperphosphorylation that mobilizes RB to deactivate E2 family (E2F) transcription factors, thereby driving cells into senescence. STING-IRF3-RB signaling plays a notable role in hepatic stellate cells (HSCs) within various murine models, pushing activated HSCs toward senescence. Accordingly, IRF3 global knockout or conditional deletion in HSCs aggravated liver fibrosis, a process mitigated by the CDK4/6 inhibitor. These findings underscore a straightforward yet vital mechanism of cGAS-STING signaling in inducing cellular senescence and unveil its unexpected biology in limiting liver fibrosis.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

Login

Don't have an account? Please register
Account*
Password*
Code*
Refresh
Forgot password?
Logging in indicates that you have read and accepted the Registration Agreement and User Agreement
Log in with other accounts

New User Registration

Already have an account?
First Name*
Middle Name
Last Name*
Organization*
Organization Type*
Country/State*
Email Address*
Code*
Set Password*
Confirm password*
Refferal Code*

Reset Password

Return to
Email*
Code*
New password*
Confirm password*